Medicare AdvantageCoverageMedium impact
MA08.049p, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated medical necessity criteria and medical coding requirements for Paclitaxel Protein-Bound Particles (Abraxane) for injectable suspension. This affects both the documentation requirements for medical necessity and coding guidelines for this oncology drug.
Action Required
By July 28, 2025: Billing team and oncology providers must review updated medical necessity criteria for Abraxane (paclitaxel protein-bound particles). Update documentation templates to ensure compliance with new medical necessity requirements. Review and update any coding guidelines for this medication in billing system. Failure to meet updated criteria may result in claim denials.